Bacteriophage-Resistant Staphylococcus aureus Mutant Confers Broad Immunity against Staphylococcal Infection in Mice

Rosanna Capparelli1, Nunzia Nocerino1, Rosa Lanzetta2, Alba Silipo2, Angela Amoresano2, Chiara Giangrande2, Karsten Becker3, Giuseppe Blaiotta4, Antonio Evidente4, Alessio Cimmino4, Marco Iannaccone1, Marianna Parlato1, Chiara Medaglia4, Sante Roperto5, Franco Roperto5, Luigi Ramunno4, Domenico Iannelli4

1 Faculty of Biotechnology, University of Naples, Portici, Naples, Italy, 2 Department of Organic Chemistry and Biochemistry, University of Naples, Naples, Italy, 3 Universitätsklinikum Münster Institut für Medizinische Mikrobiologie, Münster, Germany, 4 School of Agriculture, University of Naples, Portici, Naples, Italy, 5 Department of Pathology and Animal Health, University of Naples, Naples, Italy

Abstract

In the presence of a bacteriophage (a bacteria-attacking virus) resistance is clearly beneficial to the bacteria. As expected in such conditions, resistant bacteria emerge rapidly. However, in the absence of the phage, resistant bacteria often display reduced fitness, compared to their sensitive counterparts. The present study explored the fitness cost associated with phage-resistance as an opportunity to isolate an attenuated strain of S. aureus. The phage-resistant strain A172 was isolated from the phage-sensitive strain A170 in the presence of the Msa phage. Acquisition of phage-resistance altered several properties of A172, causing reduced growth rate, under-expression of numerous genes and production of capsular polysaccharide. In vivo, A172 modulated the transcription of the TNF-α, IFN-γ and IL-1ß genes and, given intramuscularly, protected mice from a lethal dose of A170 (18/20). The heat-killed vaccine also afforded protection from heterologous methicillin-resistant S. aureus (MRSA) (8/10 mice) or vancomycin-intermediate S. aureus (VISA) (9/10 mice). The same vaccine was also effective when administered as an aerosol. Anti-A172 mouse antibodies, in the dose of 10 µl/mouse, protected the animals (10/10, in two independent experiments) from a lethal dose of A170. Consisting predominantly of the sugars glucose and galactose, the capsular polysaccharide of A172, given in the dose of 25 µg/mouse, also protected the mice (20/20) from a lethal dose of A170. The above results demonstrate that selection for phage-resistance can facilitate bacterial vaccine preparation.

Introduction

Staphylococcus aureus can cause minor infections as well as life-threatening diseases. Endocarditis, osteomyelitis, pneumonia, surgical wound and intravascular device infections caused by S. aureus represent a major public health concern [1–3]. In the United States, about 60% of nosocomial S. aureus bloodstream infections and 40–60% of surgical wound infections are caused by methicillin-resistant strains of S. aureus (MRSA) [3]. One of these MRSA strains has been reported to cause an alarming number of necrotizing fasciitis cases [3]. Strains of S. aureus with reduced susceptibility to vancomycin are also emerging [2,4]. In the wake of the rising antimicrobial resistance [5], new strategies for the control of S. aureus infections are needed. This study describes the development of a vaccine active against S. aureus.

In the presence of an antibiotic or a bacteriophage (a bacteria-attacking virus), resistance is clearly beneficial to the bacteria. As might be expected, in such conditions, resistant bacteria are swift to emerge [6]. However, in vivo and in vitro experiments demonstrate that, in the absence of the antibiotic or phage, resistant bacteria often display reduced fitness compared to their sensitive counterparts [6–8]. This fitness cost is particularly high in the case of phage-resistant bacterial strains. To infect bacteria, phages often select an essential component of the bacterial cell wall as a receptor [8]. To gain resistance, bacteria must dispose of this component or alter its conformation [8]. However, this strategy is costly to bacteria, which often become less virulent or avirulent.

The present study explored the cost of phage resistance to isolate an attenuated strain of S. aureus. In a mouse model of infection, this phage-resistant strain prevented infections from diverse and clinically relevant S. aureus strains.

Materials and Methods

Bacteria

S. aureus strains A170, A177, A179 and A181 were isolated from clinical samples collected from patients with infected surgical wounds (one of the patients had diabetes; one wounds from a car...
monosaccharides were prepared as described [12] and analyzed gas.

Animal Care Committee of the University of Naples (permit expressed as CFU/g. Animal experiments were approved by the forming units (CFU) were evaluated by the plate count assay and mice). Organs were dissected and weighed. Samples were displayed about 1.6

Titration of anti-A172 antibodies

Mice were immunized with the A172 strain (10⁸ CFU/mouse) and two weeks later sacrificed and the blood pooled. The protein A gene is under-expressed in the A172 strain. Yet, to avoid interference with the protein A possibly present on the bacterial surface, the wells of a 96-well plate (Falcon, Milan) were coated with the S. aureus protein A negative strain Wood 46 [11], quenched with 3% bovine serum albumin (50 µl/well; 2 h), washed with PBS, incubated with anti-A172 serum diluted (10⁻²–10⁻¹) in PBS (50 µl/well; 2 h), washed with PBS and incubated, in succession, with peroxidase-labelled rat anti mouse IgG (50 µl/well; 2 h) and peroxidase substrate (100 µl/well; Bio-Rad, Milan).

Carbohydrate analysis

Teichoic acids from the A170 (A170TA) and A172 (A172TA) strains were isolated by plating dilutions of overnight susceptible cultures on TSA. Mice vaccinated with the A172 strain (25 µg/mouse) were fully protected against a lethal

Capsular polysaccharide purification

The A172 strain (100 ml) was grown in TSB. When in the exponential growth phase, the culture was centrifuged (8 × 10⁶ to 8 × 10⁸ CFU/mg/l) for 10 min. When inspected on the day of infection, the lungs displayed about 1.6 × 10⁵ ± 5.5 × 10⁵ CFU/mouse (average of 3 mice). Organs were dissected and weighed. Samples were homogenized in 1 ml saline and serially diluted in saline. Colony forming units (CFU) were evaluated by the plate count assay and expressed as CFU/g. Animal experiments were approved by the Animal Care Committee of the University of Naples (permit number 86/609/EEC).

Isolation of the phage-resistant strains

Phage Mα was isolated from the S. aureus strain A170 following induction with mitomycin [10]. Phages Mα1, Mα2 and Mα3 were isolated from S. aureus strains A177, A179 and A181, respectively; phage release was again induced with mitomycin [10]. Phage-resistant S. aureus strains A172, A178, A180 and A182 were isolated by plating dilutions of overnight susceptible cultures on TSA containing increasing concentrations of the phage used for selection. Ten single colonies growing at the highest phage concentration were selected and subcultured twice on TSA agar in the absence of phage. To ensure stability of resistance, two colonies from each phage-resistant strain were further subcultured (20 times or more) in the absence of phage. Induction of the phage-resistant strains (including A172) with mitomycin excluded the presence of prophages in these strains.

Titration of anti-A172 antibodies

Mice were immunized with the A172 strain (10⁸ CFU/mouse) and two weeks later sacrificed and the blood pooled. The protein A gene is under-expressed in the A172 strain. Yet, to avoid interference with the protein A possibly present on the bacterial surface, the wells of a 96-well plate (Falcon, Milan) were coated with the S. aureus protein A negative strain Wood 46 [11], quenched with 3% bovine serum albumin (50 µl/well; 2 h), washed with PBS, incubated with anti-A172 serum diluted (10⁻²–10⁻¹) in PBS (50 µl/well; 2 h), washed with PBS and incubated, in succession, with peroxidase-labelled rat anti mouse IgG (50 µl/well; 2 h) and peroxidase substrate (100 µl/well; Bio-Rad, Milan).

Carbohydrate analysis

Teichoic acids from the A170 (A170TA) and A172 (A172TA) isolates were prepared as described [12] and analyzed gas chromatography-combined mass spectrometry. Monosaccharides were identified as acetylated O-methyl glycosides derivatives, fatty acids or O-methyl ester derivatives. After methanolic HCl (2 M HCl/CH₃OH; 85°C, 24 h) and acetylation with acetic anhydride in pyridine (85°C; 20 min), samples were analyzed by gas chromatography-combined mass spectrometry (GC-MS) and compared with standards. GC-MS analyses were carried out on a Hewlett-Packard 5890 instrument using SPB-5 capillary column (0.25×3 m; Supelco, PA). Ring size and attachment points were determined by methylation analysis as described [13]. The sample (1–2 ng) was methylated with CH₃/NaOH in DMSO, hydrolysed with 2 M trifluoroacetic acid (100°C, for 4 h), reduced with NaBD₄, acetylated with acetic anhydride in pyridine and analyzed by GC-MS. The temperature programme was: 150°C for 5 min and then 5°C/min to 300°C over 10 min.

Figure 1. Pulsed field electrophoresis pattern of Sma I digests from the Staphylococcus aureus A170 strain. The A172 strain (not shown) displayed an identical pattern. M: DNA Size Standard, Lambda Ladder (Concatemers of λ cl857 Sam7) (Bio-Rad Laboratories, Hercules, CA).
doi:10.1371/journal.pone.0011720.g001
Benefits of Phage Resistance
dose of A170 bacteria. This biologically active fraction (3.4 g) was hydrolysed with 0.1 M HCl at 100°C for 48 h. The mixture was neutralized with 2 M NaOH and reduced with sodium borohydride in distilled water (3 g/0.5 ml). The alditiols were acetylated with pyridine (100 µl) and acetic anhydride (100 µl) at 85°C for 30 min. The monoses were identified as acetaltidols by gas liquid chromatography (GLC) [14] using the Agilent GC-MS 7890A instrument (Waghaeusel-Wiesental, Germany) equipped with a capillary column (30 m × 0.25 mm, 0.25 µm film thickness) of SPB-5 (Sigma Aldrich, Milan, Italy) and applying a temperature gradient of 150°C (3 min) to 320°C at 3°C/min.

**Detection of A172 revertants**

Individual wells of 96-well plates were filled with 200 µl TSB medium and inoculated with one colony of A172 bacteria isolated from mice vaccinated with the same strain and then grown in vitro for 10 generations under stress conditions (10 µg/ml novobiocin) [15]. Bacteria were grown for 3 h at 37°C. Individual cultures (10⁷ CFU/200 µl) were quantitatively spread over a phage lawn (10⁹ PFU/5 ml soft agar). Bacteria were thus surrounded by large numbers of virus particles. Plates were inspected for the presence of plaques of lysis during the next 4 days. The detection limit of the test was established by carrying out the test on the same A172 cultures spiked with 12, 6, 3 or 1 A170 M⁸⁻⁴-sensitive bacteria. The dilutions with 12, 6, 3 or 1 A170 bacteria were assayed by plate count in triplicate.

The presence of revertants was also investigated by an independent method, based on the increase of phage titre of a liquid culture upon addition of phage-sensitive bacteria [16]. A172 bacteria grown in the presence of novobiocin (10⁹ CFU/200 µl) were incubated for 1 h with the M⁸⁻⁴ phage (10¹⁴ PFU). The cultures were then transferred quantitatively on a lawn of the A170 M⁸⁻⁴-sensitive bacteria (10⁹ CFU/ml soft agar) to determine whether the original phage titre increased. The detection limit of the test was established by testing in parallel the phage titre increase that occurred in the same A172 cultures (10⁹ CFU/200 µl) spiked with 12, 6, 3 or 1 A170 M⁸⁻⁴-sensitive bacteria. The dilutions with 12, 6, 3 or 1 A170 bacteria were assayed as described above.

**Phage lysis inhibition**

A170 or A172 bacteria (10⁵ CFU/100 µl) were grown (4 h) in 2 ml TSB, in the presence or absence of: 5-20 mM N-acetyl-glucoasamine (GlcNAc), 5-20 mM glucose (Sigma, Milan), 0.1-4 nmol/tube teichoic acid from A170 (A170TA) or A172 (A172TA). The M⁸⁻⁴ phage (10⁹ PFU/tube) was then added and bacterial growth (OD₆₅₀) measured 30 min later.

**Phage inactivation by N-acetyl-glucoasaminidase**

A170 or A172 bacteria (10⁵ CFU/100 µl) were grown (4 h) in 2 ml TSB, in the presence or absence of N-acetyl-glucoasaminidase from Canavalia ensiformis (Sigma; 4 U/tube). The M⁸⁻⁴ phage was then added (10⁹ PFU) and bacterial growth (OD₆₅₀) measured 30 min later.

**Pulsed-field electrophoresis of S. aureus strains**

The procedure adopted was that described in [17]. Briefly, inserts of intact DNA were digested in 200 µl of appropriate buffer supplemented with 40 U of Snal I (Promega, Milan). Pulsed field gel electrophoresis (PFGE) of the restriction digests was performed by using the CHEF system (Bio-Rad Laboratories, Hercules, CA, USA) with 1% (wt/vol) agarose gels and 0.5X TBE as running buffer, at 10°C. Restriction fragments were resolved in a single run, at constant voltage of 6 V cm⁻¹ and an orientation angle of 120° between electric fields, by a single phase procedure for 24 h with a pulse ramping between 1 and 50s.

**Other methods**

The transcription level of bacterial virulence genes and mouse cytokine genes was analyzed by real-time reverse transcription PCR (RT-PCR) as described [18]. Fluorescein isothiocyanate-labelled A170 (A170³º) and A172 (A172³º) bacteria were prepared as described [19]. Troponin was measured using the Mini Vidas automated immunoassay analyzer and the Vidas troponin kit (bioMérieux, Florence, Italy). The sequence type of the S. aureus strains was determined by sequencing the hypervariable region of S. aureus protein A gene (spa) as described [20]. The spa types were assigned using the Ridom spa-server (http://spaserver.ridom.de/). Multilocus sequence typing (MLST) of S. aureus strains was carried out as described [21]. The bacterial genes eta, etb, tst, lukS-PV-lukF-PV, lukE-lukD and lukM, (coding for the exfoliative toxin A, exfoliative toxin B, toxic shock syndrome toxin1, Panton-Valentine leukocidin components S and F, the leukotoxin LukELukD, and the leukotoxin LukM, respectively) were detected by PCR [10]. The staphylococcal enterotoxin (se) genes se-a, se-b, se-c, se-d, and se-e were detected as described [22]. The restriction endonucleases analysis-enterotoxin gene cluster (REA-eg) type was carried out as described [23]. Survival rates of mice were analyzed using Fisher’s exact test. Bacterial counts and gene expression levels were analyzed using the.
paired t test (P values are two-tailed values). The molar concentration of the teichoic acids from the S. aureus strains A170 and A172 were calculated attributing to A170 and A172 the molecular weight of 6350 daltons (the average molecular weight of the teichoic acid from S. aureus strain Copenhagen, which ranges from 5400 to 7300 daltons) [24].

Results

Isolation and characterization of A172

The strains A170 and A172 were positive for the exfoliative toxin B, the Panton-Valentine leucokidin, while negative for the exfoliative toxin A, toxic shock syndrome toxin 1, the leukotoxin LukELukD, the leukotoxin LukM and the staphylococcal enterotoxins-a, -b, -c, -d and -e. The strains A170 and A172 displayed also the same egg type (egc-4), the multilocus sequence type (ST 45) and spa-type (t6668) (spa-type repeats succession: 08-16-02-16-34-13-17-34-34-34-34-34, equivalent to Kreiswirth’s IDs: XKAKBEMBBBB). According to the Ridom spa-server (http://spaserver.ridom.de), t6668 represents a novel spa type. PFGE analysis displayed a close genetic relation between the parental phage M6a-sensitive strain A170 and the derivative phage-resistant strain A172, as proved by the identical PFGE pattern of the SmaI digests (Figure 1). A172 was isolated by growing the parental strain A170 in the presence of increasing concentrations of the M6a phage [10]. In addition to M6a, the strain A172 is also resistant to phages M6a1, M6c and M6a5. Prolonged liquid subculture for several months in the absence of phage or prolonged storage at −80°C did not alter the resistance of A172 to M6a.

The strain was also highly stable in vivo. A172 bacteria were isolated from a vaccinated mouse, for 15 generations under stress conditions (10 µg/ml novobiocin) [15] and used to establish 400 independent bacterial cultures, which yielded a total number of about 4×10¹¹ bacteria (10⁶, the number of cells/culture×400, the number of cultures). Plated with phage in excess (10¹² PFU/5 ml soft agar), the 400 independent bacterial cultures did not yield any plaque of lysis. Control cultures (10⁹ CFU A172/200 µl spiked with 3 A170 bacteria), assayed in triplicate in three independent experiments, displayed all at least one plaque and, on average, 2.2±0.7 plaques/culture (number of replicas: 9). The absence of A172 revertants was confirmed in a second independent experiment. When the M6a phage (10⁸ PFU) was mixed with the A172 bacteria grown under stress conditions (10⁸ CFU/200 µl), no measurable increase in the phage titre occurred. Control cultures (10⁶ CFU A172/200 µl spiked with 3 A170 bacteria), compared to the non-spiked cultures, displayed an increase in phage titre from 1.4×10³±2.4×10³ to 1.2×10⁴±0.5×10³ (n: 9; P: 0.0057). Conservatively, it is estimated that A172 revertants occur at a frequency <3×10⁻⁷.

In liquid culture, compared to the parental strain, A172 formed colonies with the tendency to clump together starting at the early stationary phase (Figure 2A–B). Bacterial suspensions of A170 and A172 with the same density (OD₆₀₀: 0.6) were assayed by plate count. In three independent experiments, A170 cultures contained about 3 fold as many CFU as the A172 cultures (3.4±0.7×10⁶/0.7 plaques/culture (number of replicas: 9). The receptor of the M6a phage is the N-acetylglucosamine.

Phages often use teichoic acids for adsorption on the cell wall of Gram positive bacteria. They can use as receptor the glucose side chains of Bacillus subtilis teichoic acids [26,27] or the N-acetylglucosamine (GlcNAc) side chains of S. aureus [28]. To identify the receptor site of the M6a phage, the A170 and A172 strains were grown in the presence or absence of 5–20 mM GlcNAc or 5–20 mM glucose. GlcNAc inhibited the lysis of A170 by phage M6a, while glucose did not. GlcNAc inhibition was dose-dependent (Figure 3A–B). The experiment was repeated using the teichoic acid from (A170) or from (A172) as inhibitor. Since

Figure 4. Expression levels of S. aureus A170 and A172 virulence factors. Acquisition of phage-resistance by A172 is accompanied by extensive alterations in virulence gene expression levels. Out of the 14 ORFs examined, 13 are significantly under-expressed, compared to the phage-sensitive strain A170. Bacteria were collected for transcriptional analysis during the exponential growth phase (SA1070 spa, IgG binding protein A precursor); SA0112 (hypothetical protein, similar to cysteine synthase); SA0184 (hypothetical protein); SA039 (glycine betaine aldehyde dehydrogenase gbsA); SA2265 (olfoligopeptide transporter substrate binding protein); SA2374 (glycine betaine aldehyde); SA2266 (olfoligopeptide transporter substrate binding protein); SA2406 (glycine betaine aldehyde dehydrogenase gbsA); SA2459 (Ica-N-glycosyltransferase); SAR216 (groEL; chaperonin GroEL); SAR2117 (groES; co-chaperonin GRES). ORFs numbers correspond to the S. aureus N315 genome sequence. Gene designations (when known) and proteins function are shown in parentheses.

doi:10.1371/journal.pone.0011720.g004
the quantity of teichoic acid that is isolated from the A170 or A172 strains varies significantly (2.4 mg from 10^{10} CFU A170; 0.9 mg from 10^{10} CFU A172), the experiment was conducted using an ample concentration range of the A170TA and A172TA reagents. Under these conditions, phage inactivation occurred with A170TA, but not with A172TA (Figure 5C). A170 bacteria were then treated with N-acetylglucosaminidase (4 U/tube; 2 h at 37°C). Enzymatic hydrolysis of GlcNAc from the A170 bacteria destroyed phage lysis capacity (Figure 5D). Finally, analysis of teichoic acids from the A170 (wild) and A172 (mutant) strains of *S. aureus* displayed the absence of ribitol (Figure 6A) and terminal GlcNAc (t-GlcNAc) residues (Figure 6B) from A172TA. Collectively, the experiments described above demonstrate that A172 conforms with the tendency of several bacterial species - *B. subtilis* [26,27], *S. aureus* [28], *Salmonella enterica* [18,29] - to acquire phage-resistance by altering a cell wall polysaccharide component.

The A172 strain prevents *S. aureus* infection

For a more succinct presentation of the results, the distinctive features of the experiments described in this and the following sections are detailed in the Tables. One group of mice was immunized with A172 live (A172-L) and two weeks later infected with a lethal dose of A170. At the time of infection, in the serum of immunized animals the titre of the antibodies against A172-L ranged from 1:5000 to 1:12000. Control mice were also infected with a lethal dose of A170. The A172-L vaccine protected 90% of the mice (surviving mice: 18/20) from A170, while the control mice (10/10) died within 4 days (P: 0.008; Table 1, experiment 1). When examined at the end of the experiment (14 days after challenge), the kidneys of surviving A172-L treated animals displayed significantly fewer CFU compared to the kidneys of the control mice at the time of death (Table 1, experiment 1).
To exclude that the above results represented the response elicited by a sublethal infection with live *S. aureus*, mice were infected with a sublethal dose of A170 and two weeks later challenged with a lethal dose of A170. There was no significant difference in surviving between immunized and control mice (P: 1; Table 1, experiment 2). Thus, the protective response described above is to be ascribed specifically to A172.

Being a live vaccine, A172 poses the risk of reverting to the virulent phenotype. This risk is remote (see the section “Isolation and morphological characterization of A172”), albeit considerable when the use of a large number of vaccine doses is prospected.

The study therefore explored whether A172 remained protective when the use of a large number of vaccine doses is prospected. The study therefore explored whether A172 remained protective once it was heat-killed (15 min at 100 °C). Mice were vaccinated with heat-killed vaccine (A172-HK) and 2 weeks later infected with a lethal dose of A170. The vaccine was protective also in this form (P: 0.004; Table 1, experiment 3).

When the interval between vaccination and challenge was extended to 20 weeks, control mice all died within 4 days (10/10); the vaccinated mice (37/40) were alive 14 days after challenge (P: 0.004; Table 1, experiment 4). Thus, the protection provided by the vaccine lasts at least 20 weeks.

One more experiment was designed to ascertain whether also A170 - in the heat-killed form (A170-HK; 15 min at 100 °C)- was protective. No significant difference in survival between immunized and control mice was observed (P: 1; Table 2, experiment 5).

### Additional properties of the A172 vaccine

The efficacy of the A172-HK vaccine was tested against two methicillin-resistant *S. aureus* (MRSA) (A174 and A175) and one vancomycin-intermediate *S. aureus* (VISA) (A176) isolates derived from patients with staphylococcal infections. Three groups of mice were immunized with A172-HK and 20 weeks later infected with a lethal dose of the A174, A175 or A176 isolates. The difference in survival between vaccinated and control mice was statistically significant in each case (P: 0.01–0.02; Table 2).

Patients with cystic fibrosis are highly susceptible to *S. aureus* lung infection [30]. *S. aureus* is also one of the most common causes of pneumonia in paediatric and adult populations [31].

The study therefore explored the efficacy of A172-HK against lung infections. Mice were immunized by aerosol with A172-HK and 20 weeks later infected with A170 by the same route. The vaccine was also effective when administered by aerosol (P: 0.004; Table 3).

Collectively, the experiments described in this and the preceding section demonstrate that A172-HK protects mice against a lethal dose of *S. aureus*; protection correlates with increased survival and reduced colonization lasting at least 20 weeks and extending into drug-resistant isolates of *S. aureus*; the vaccine is effective when administered, in single dose and without adjuvant, by the intramuscular or aerosol routes.

### Anti-A172 antibodies protect against *S. aureus* A170 infection in vivo

Two groups of mice (control mice) were injected intramuscularly with normal mouse serum (10 µl or 20 µl diluted 1:10 with sterile saline, respectively). Two more groups of mice were treated intramuscularly with serum from mice immunized with A172-HK (10 µl or 20 µl diluted 1:10 with sterile saline, 50 µl of PBS).

### Table 1. Active protection of A172 in mice challenged with *S. aureus* strain A170.

| Exp | Dose CFU/mouse | Vaccine | Interval vaccination challenge (weeks) | Challenge | Pathogen | Route | Survival | P value | CFU/g (mean ± SD) |
|-----|----------------|---------|--------------------------------------|-----------|----------|-------|----------|---------|------------------|
| 1   | 10⁶            | A172-Lc | -                                    | 10⁶       | A170     | Im    | 18/20    | 0.008   | 266±11           |
| 2   | 5×10⁶          | A170    | -                                    | 10⁶       | A170     | Im    | 0/10     | 0.05    | 5.6×10⁵±3.5×10⁵  |
| 3   | 10⁶            | A172-HK | -                                    | 10⁶       | A170     | Im    | 19/20    | 0.004   | 260±25           |
| 4   | 10⁶            | A172-HK | -                                    | 10⁶       | A170     | Im    | 19/20    | 0.004   | 3.5×10⁶±1.8×10⁶  |
| 5   | 10⁶            | A170    | -                                    | 10⁶       | A170     | Im    | 0/10     | 0.05    | 5.2×10⁵±3.3×10⁵  |

aColony forming units per g of kidneys (experiments 1–4) or lungs (experiment 5); values calculated on 3 mice.

bTwo tailed Fisher’s exact test.

A172 Live.

²Intemuscular.

³P<0.001.

¹Heat killed A172.

doi:10.1371/journal.pone.0011720.t001
respectively. The titre of the antibodies against A172-HK was 1:8000. The next day, the mice were all challenged with a lethal dose of S. aureus A170. Survival was monitored for seven days. In two independent experiments, the antibodies against A172-HK - given at the dose of 10^8 ml/mouse - provided protection to all the mice (10/10) (P < 0.01; Table 4, experiments 1 and 2). Instead, the same serum given at the dose of 20 ml/mouse - killed 40%–50% of the mice (P 0.05–0.06; Table 4, experiments 1 and 2). Thus, anti-A172 antibodies can be protective or detrimental, depending upon the dose being given. This phenomenon has been described since the development of serum therapy [32]. In mouse models of Streptococcus pneumoniae [32] and Cryptococcus neoformans [33], antibody-mediated protection was also observed within a narrow dose range. Since the therapeutic use of antibodies in humans is sometimes associated with myocardial damage [34,35], mice passively immunized with antibodies against A172-HK were tested for evidence of heart damage by measuring the level of the cardiac troponin T in the serum. This marker is highly specific for myocardial damage [34]. Mice treated with 20 ml antibodies, compared to those treated with 10 ml, displayed a statistically significant higher level of serum troponin T (0.09±0.01 ng/ml vs 0.02±0.01 ng/ml; P: 0.001). It was not investigated whether heart damage was the primary cause of death or a secondary complication of antibody administration. Mice treated with 10 ml or 20 ml antibodies displayed both significantly fewer CFU compared to the mice treated with normal mouse serum (Table 4, experiments 1 and 2).

In an independent experiment, mice were immunized with 10 ml of anti-A172 mouse serum absorbed with rat anti total mouse immunoglobulin fraction (5–10 ml) and diluted to 100 ml with sterile saline. The next day, the mice were challenged with a lethal dose of S. aureus A170. Absorption of anti-A172 mouse serum completely eliminated the protective effect of the serum (Table 4, experiments 3). Collectively, the above results demonstrate that the passive protection shown by the antibodies against A172-HK is dose dependent and specific (residing in the antibody fraction of the serum).

Table 2. Protection of heat killed vaccine A172 against drug-resistant S. aureus strains.

| Vaccination | Interval vaccination challenge (weeks) | Challenge | CFU/g\(^{a}\) (mean ± SD) |
|-------------|---------------------------------------|-----------|----------------------------|
| Dose (CFU/mouse) | Vaccine | Route | Dose (CFU/mouse) | Pathogen | Route | Survival | P value\(^{b}\) | |
| 10^8 | A172-HK\(^{c}\) | Im\(^{d}\) | 20 | 10^8 | A174 | Im | 8/10 | 0.02 | 250±22^g |
| - | - | - | 0/10 | - | - | - | 6.7×10^6±1.8×10^6 |
| 10^8 | A172-HK | - | 20 | 10^8 | A175 | Im | 9/10 | 0.01 | 330±37^g |
| - | - | - | 0/10 | - | - | - | 5.8×10^6±1.1×10^6 |
| 10^8 | A172-HK | - | 20 | 10^8 | A176 | Im | 9/10 | 0.01 | 380±26^g |
| - | - | - | 0/10 | - | - | - | 5.5×10^6±3.6×10^6 |

\(^{a}\)Colony forming units per g of kidneys; values calculated on 3 mice.
\(^{b}\)Two tailed Fisher’s exact test.
\(^{c}\)Heat killed A172.
\(^{d}\)Intramuscular.
P<0.001.
doi:10.1371/journal.pone.0011720.t002

The A172 strain controls inflammation

Ten mice were immunized intramuscularly with A172-HK (10^8 CFU/mouse). A172 modulated transcription of the genes coding for the pro-inflammatory cytokines TNF-\(\alpha\), IFN-\(\gamma\) and IL-1\(\beta\), while inducing that of the genes coding for the anti-inflammatory cytokines IL-4 and IL-6, when these genes were analyzed by RT-PCR, 24 and 48 h after immunization (Figure 7). The same pattern of cytokine production was observed in mice immunized with A172-HK and 20 weeks later infected with A170 (data not shown). Given the abundant release of pro-inflammatory cytokines during S. aureus infection [36–37], this property of A172 is biologically relevant.

Table 3. Protection of heat killed vaccine A172 administered by aerosol.

| Vaccination | Interval vaccination challenge (weeks) | Challenge |
|-------------|---------------------------------------|-----------|
| Dose (CFU/mouse) | Vaccine | Route | Dose (CFU/mouse) | Pathogen | Route | Survival | P value\(^{b}\) | CFU/g\(^{a}\) (mean ± SD) |
| 10^8 | A172-HK\(^{c}\) | Aer\(^{d}\) | 20 | 10^8 | A170 | Aer | 19/20 | 0.004 | 216±3^g |
| - | - | - | 0/10 | - | - | - | 7.1×10^6±3.1×10^6 |

\(^{a}\)Colony forming units per g of kidneys; values calculated on 3 mice.
\(^{b}\)Two tailed Fisher’s exact test.
\(^{c}\)Heat killed A172.
\(^{d}\)Aerosol.
P<0.001.
doi:10.1371/journal.pone.0011720.t003

Benefits of Phage Resistance
Selection for phage resistance as a general approach for vaccine production

Three groups of mice were immunized (10^6 CFU/mouse, intramuscularly) with the M\textsuperscript{S\textsubscript{a}1}-resistant strain A178 (derived from the M\textsuperscript{S\textsubscript{a}1}-susceptible isolate A177), M\textsuperscript{S\textsubscript{a}2}-resistant strain A180 (derived from the M\textsuperscript{S\textsubscript{a}2}-susceptible isolate A179) or M\textsuperscript{S\textsubscript{a}3}-resistant strain A182 (derived from the M\textsuperscript{S\textsubscript{a}3}-susceptible isolate A181), respectively. Two weeks later, immunized and control mice were challenged with A170 (10^8 CFU, intramuscularly). The phage-resistant strains all provided protection in terms of survival and level of host colonization (Table 5; P: 0.01–0.02) and – like A172 - all lost t-GlcNAc (data not shown) while all gained the capacity to secrete capsular polysaccharide (Figure 3). The experiment demonstrates the general applicability of selection for phage resistance as a means to curb bacterial virulence. The experiment demonstrates also how different S. aureus isolates use the same defence strategy against different phages.

The capsular polysaccharide from A172 provides protection

Capsular polysaccharide (CP) production is a characteristic common to the four protective strains (A172, A178, A180, A182) (Figure 3). In an attempt to identify the protective component of A172, the CP from this strain (CP-A172) was purified and analyzed by gas liquid chromatography (GLC). CP-A172 contains glucose and mannose in the molar ratio of 3:1 and traces (molar ratio: 0.3) of galactose and GlcN (Figure 8). Immunization of mice with CP-A172 (25 mg/mouse) or treatment with the serum from mice immunized with CP-A172 (10 ml diluted 1:10 with sterile saline/mouse) protected mice against a lethal dose of A170 (P: 0.004; Table 6, experiments 1–2).

Discussion

Several virulence factors of S. aureus are being investigated for their potential use as vaccines [37–38]. However, in view of the numerous virulence factors produced by this pathogen [39], it is unlikely that a single component vaccine might protect against a multitude of virulence factors. Also, virulence genes often display high levels of variability, as result of the selection pressure to evade the immune system of the host [40]. The single antigen may therefore have limited distribution among clinical isolates or may not be expressed in vivo. The objective of the present study was to...
develop a live attenuated *S. aureus* strain containing multiple antigens and therefore likely to elicit cross-protection against a spectrum of pathogenic strains. The attenuated strain (A172) proved effective as vaccine even when heat-killed. Thus, heat-killed A172 (A172-HK) possesses the advantages of a multiple component vaccine, without the problems of safety (reversion to phage sensitivity and the accompanying virulent phenotype), distribution and manufacturing of the live vaccines [41].

Phage-resistance often (though not always) occurs at a fitness cost [6,7]. This trade-off explains why phage-resistant and phage-sensitive bacteria coexist [42]. Bacterial selection for phage-resistance was therefore exploited as an approach to isolating an attenuated strain of *S. aureus*. The approach had already been used successfully to produce a vaccine against *Salmonella enterica* serovar *Paratyphi B* [18]. The phage-sensitive strain A170, following growth in vitro in the presence of the MSa phage, yielded the phage-resistant strain A172. Given their common origin, the two strains share several properties, but display also crucial differences. They share the spa-type (t6668), the MLST type (ST 45), the egc type (egc-4) and part of the genome (Figure 1). At the same time, A170 and A172 differ in their teichoic acid structure and the capacity to secrete CP. The teichoic acids of A172 lack the terminal GlcNAc residues (Figure 6B) that phages often use for adsorption on the cell wall of *S. aureus* [28]. More importantly, GlcNAc and the teichoic acids from A170 (A170TA) inhibit lysis by the M8a phage, while glucose or the teichoic acids from A172 (A172TA) do not (Figure 5C). These results suggest that A172 gained phage-resistance by losing the phage adsorption site (terminal GlcNA). However, A172 also displays CP production, a strategy that some bacteria put in action to mask their phage adsorption site [43]. In conclusion, while teichoic acid alteration is the likely mechanism adopted by A172 to gain phage resistance, the contribution of CP production cannot be excluded.

In a mouse model of infection, A172-HK elicited high levels of protection against lethal doses of the A170 strain (P 0.004; Table 1, experiment 3). A single dose of A172-HK, without use of adjuvant, was fully protective after vaccine administration by the intramuscular or aerosol routes and protection lasted at least 20 weeks (Tables 1–3). Significantly, A172-HK was effective against methicillin-resistant (MRSA) or vancomycin-intermediate clinical isolates of *S aureus* (VISA) (Table 2). Sometime cross-protection has been attributed to the persistence of the vaccine strain within the host [44]. This possibility can be excluded in the present study since the vaccine persists in the immunized animals for only 8

| Vaccination | Interval vaccination-challenge | Challenge |
|-------------|-------------------------------|----------|
| Dose (CFU/mouse) | Strain | Route | Dose (CFU/mouse) | Strain | Route | Survival | P value<sup>b</sup> | CFU/g<sup>a</sup> (mean ± SD) |
| 10<sup>8</sup> | A178 | Im | 20 | 10<sup>8</sup> | A177 | Im | 9/10 | 0.01 | 230 ± 40<sup>c</sup> |
| - | - | - | - | - | - | - | - | - | 4.6 × 10<sup>6</sup> ± 1.5 × 10<sup>6</sup> |
| 10<sup>8</sup> | A180 | - | 20 | 10<sup>8</sup> | A179 | Im | 10/10 | 0.01 | 160 ± 34<sup>c</sup> |
| - | - | - | - | - | - | - | - | - | 5.3 × 10<sup>5</sup> ± 2 × 10<sup>5</sup> |
| 10<sup>8</sup> | A182 | - | 20 | 10<sup>8</sup> | A181 | Im | 8/10 | 0.02 | 180 ± 25<sup>c</sup> |
| - | - | - | - | - | - | - | - | - | 3.5 × 10<sup>5</sup> ± 1.2 × 10<sup>5</sup> |

<sup>a</sup>Colony forming units per g of kidneys; value calculated on 3 mice.
<sup>b</sup>Two tailed Fisher’s exact test.
<sup>c</sup>P < 0.001.

doi:10.1371/journal.pone.0011720.t005

Figure 8. Gas liquid chromatography profile of monosaccharides obtained by acid hydrolysis of the capsular polysaccharide from *S. aureus* A172. Abundance expresses the relative ratio between monosaccharides.

doi:10.1371/journal.pone.0011720.g008
the expression of pro-inflammatory cytokines (IFN-γ)(Figure 7). IL-6 is an anti-inflammatory cytokine controlling ed animals displayed an elevated transcription level of IL-6 polysaccharide vaccine, that has acetylated fucosamine and b distinguishes CP-A172 from the poly-N-succinyl CP-A172 are mannose and glucose (Figure 8). This feature against a lethal dose of A170 (Table 6). The main components of CP-A172 provides mice with both active and passive resistance provided sufficient ground to claim that the protective efficacy of can confer protection [45–46]. Taken together, these facts characteristic of secreting CP (Figure 3). CPs are heat stable and molecule, that acts as a protective antigen. Also, the phage-... days, while mice were challenged with virulent S. aureus 20 weeks after vaccine administration (Table 1).

Passive immunization of mice with sera from A172-HK vaccinated mice provided protection against the challenge with a lethal dose of S. aureus A170. In two independent experiments, 10/ 10 of the animals passively immunized with an individual dose of 10 μl immune serum (diluted 1:10 with sterile saline) survived, while 10/10 untreated control mice died (P: 0.01; Table 4, experiment 1). When the experiment was repeated using a higher dose (20 μl immune serum diluted 1:10 with sterile saline/mouse), 40%-50% of the animals died (Table 5, experiment 2). These results indicate that high antibody doses can be detrimental. This possibility must be considered when interpreting passive protection experiments.

A172-HK was protective in vivo, while A170-HK was not (Table 1). This suggested that A172, along with the resistance to the M\(^{\text{sa}}\) phage, also acquired the capacity to express a new molecule, that acts as a protective antigen. Also, the phage-resistant strains (A172, A178, A180, A182) all display the characteristic of secreting CP (Figure 3). CPs are heat stable and can confer protection [45–46]. Taken together, these facts provided sufficient ground to claim that the protective efficacy of A172 could reside in its CP (CP-A172). The results confirmed that CP-A172 provides mice with both active and passive resistance against a lethal dose of A170 (Table 6). The main components of CP-A172 are mannose and glucose (Figure 8). This feature distinguishes CP-A172 from the poly-N-succinyl β-1-6 glucosamine vaccine described by McKenney [45] and the capsular polysaccharide vaccine, that has acetylated fucosamine and mannosamine as major components [46].

When compared with A170 infected mice, A172-HK vaccinated animals displayed an elevated transcription level of IL-6 (Figure 7). IL-6 is an anti-inflammatory cytokine controlling the expression of pro-inflammatory cytokines (IFN-γ, IL-1β and TNF-α) [36–38]. Staphylococcal infections cause a profound release of proinflammatory cytokines, which enhance endothelial cell permeability and extravasation of bacteria from blood to the tissues [38]. In particular, elevated levels of IFN-γ cause necrosis in the kidneys of S. aureus-infected mice [37]. Thus, the A172 vaccine, inducing a balanced pro- and anti-inflammatory response, tempers the detrimental effects of an excessive inflammation.

It is not uncommon for clinical isolates to be resistant to staphylococcal phages. This finding deserves a final comment. Resistant bacteria, despite of their reduced fitness, sometimes persist because they attenuate the impact of phages on sensitive bacteria and thus contribute to maintain diversity within the bacterial population [47].

In conclusion, given the multiple virulence factors expressed by S. aureus, a whole cell bacterial vaccine would have significant potential. However, the application of these vaccines (against S. aureus and bacterial pathogens in general) is limited by the difficulty of developing reliable procedures of bacterial attenuation [41]. Selection for phage resistance promises to serve this purpose well. Of course, it must be recalled that the trade-off associated with phage resistance can be paid by the pathogen in a form other than lowered virulence. With these caveats, the evidence so far available – [18] and this article - suggests that selection for phage resistance as a means to curb bacterial virulence is not particular to the phage M\(^{\text{sa}}\) or the bacterial strain A172, but more general. Phage resistance, long considered a problem in the fight against bacteria [48], is shown here to be an opportunity.

**Author Contributions**
Conceived and designed the experiments: RC RL AA MI MP DI. Performed the experiments: NN AS CG KB GB AE AC CM SR FR LR. Analyzed the data: RC RL AA KB GB AE AC CM SR FR LR. Wrote the paper: DI.

**References**
1. Boyer JM (2005) Meticillin-resistant *Staphylococcus aureus*. Lancet Infect Dis 5: 653–654.
2. Marris E (2005) Bugs gain vital ground in their battle against drugs. Nat Med 11: 461.
3. Miller LG, Perdreau-Remington F, Rieg G, Mahdi GS, Perlroth JA, et al. (2005) Necrotising fasciitis caused by community-associated methicillin resistant *Staphylococcus aureus* in Los Angeles. N Engl J Med 352: 1445–1453.
4. Sakoulas G, Eliopoulos GM, Fowler Jr. VG, Moelling Jr. RC, Novick R, et al. (2003) Reduced susceptibility of *Staphylococcus aureus* to vancomycin and platelet microbial protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 49: 2687–2692.
5. Lowy FD (1988) *Staphylococcus aureus* infections. N Engl J Med 339: 508–512.
6. Zahid MS, Udden SM, Faraque AS, Calderwood SB, Mekalanos JJ, et al. (2008) Effect of phage on the infectivity of *Vibrio cholerae* and emergence of genetic variants. Infect Immun 76: 5266–5273.
7. Jensen MA, Faraq SM, Mekalanos JJ, Levin BR (2006) Modeling the role of bacteriophage in the control of cholera outbreaks. Proc Natl Acad Sci USA 103: 4652–4657.
8. Scott AE, Timmis KR, Conneron PL, Carrillo CL, Radum KA, et al. (2007) Genome dynamics of *Campylobacter jejuni* in response to bacteriophage predation. PLOS Pathogens 3: 1142–1151.
9. Mason W, J. Blevins J, Beenken K, Wibowo N, Ojma N, et al. (2001) Multiplex PCR protocol for the diagnosis of staphylococcal infections. J Clin Microbiol 39: 3332–3338.

---

**Table 6. Active and passive protection afforded by CPA172.**

| Exp | Treatment | Dose μg/mouse | Route | Interval treatment challenge | Challenge | Dose CFU | Pathogen | Route | Survival | P value | CFU/g (mean ± SD) |
|-----|-----------|----------------|-------|-----------------------------|-----------|----------|----------|-------|----------|---------|------------------|
| 1   | CPA172    | 25             | Im    | 20 weeks                    | A170      | 10⁶      |          |        | 20/20    | 0.004   | 138±27          |
| 2   | Anti-CPA172 | 10            | Im    | 24 h                        | A170      | 10⁷      |          |        | 0/10     | 4×10⁸±10⁷       |
|     | Normal mouse serum | 10 | - | - | A170 | 10⁷ | 0/10 | 3.8×10⁸±10⁷ |

*Colonies forming units per g of kidneys; values calculated on 3 mice.

Two tailed Fisher’s exact test.

*Intramuscular.

!P<0.001.

doi:10.1371/journal.pone.0011720.t006
10. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D (2007) Experimental phage therapy against *Staphylococcus aureus* in mice. Antimicrob Agents Chemother 51: 2765–2773.

11. Lachica V, Genigeorgis C, Hoeprich P (1979) Occurrence of protein A in *Staphylococcus aureus* and closely related *Staphylococcus* species. J Clin Microbiol 10: 752–753.

12. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, et al. (1999) Inactivation of the *drf* operon in *Staphylococcus aureus* confers sensitivity to defense, protegrins, and other antimicrobial peptides. J Biol Chem 274: 8405–8410.

13. Cincanu I, Kerek F (1984) A simple method for the permeabilization of carbohydrates. Carbohydr Res 131: 209–217.

14. Ciminino A, Marchi G, Surace G, Hanuschkovicz A, Evidente A, Holst Ø (2008) The structure of the O-specific polysaccharide of the lipopolysaccharide from *Pantoaglomaria* strain FL1. Carbohydrate Res 343: 392–396.

15. Korman R (1975) Cell wall composition of novobiocin-resistant pleiotropic resistant *Staphylococcus aureus*. J Bacteriol 124: 724–730.

16. Luria SE, Delbruck M (1943) Mutations of bacteria from virus sensitive to virus resistant. Genetics 28: 291–411.

17. Blaiotta G, Moschetti G, Simoni L, Mangoli R, Villani F, et al. (2001) Monitoring lactic acid bacteria strains during “calcioricotta” cheese production by restriction endonuclease analysis and pulsed-field gel electrophoresis. J Dairy Res 68: 139–144.

18. Blaiotta G, Nescirino N, Iannaccone M, Ercolini D, Parlato M, et al. (2009) Phage therapy of *Salmonella enterica*: a fresh appraisal of phage therapy. J Infect Dis 201: 52–61.

19. Weidenmaier C, Kokai-Kun J, Kristian SA, Chanturiya T, H. Kalbacher H, et al. (1999) Inactivation of *egc* and *spa* sequences in *Staphylococcus aureus* by enterotoxin gene cluster (*tec*)-mediated septic death. J Clin Invest 101: 2649–2649.

20. Mellmann A, Friedrich AW, Rosenkotter N, Rothganger J, Karch H, et al. (2006) In vivo survival of teicoplanin-resistant *Staphylococcus aureus* confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274: 8405–8410.

21. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* and closely related *S. aureus* strains isolated from meat and dairy products. Evidence for new variants of *S. aureus* AB-8802. J Appl Microbiol 97: 719–730.

22. Blaiotta G, Ercolini D, von Eiff C, Villani F, Becker K (2006) Biotyping of *Pantoaglomaria* species. J Clin Microbiol 44: 752–753.

23. Blaiotta G, Fusco V, von Eiff C, Villani F, Becker K, et al. (2004) PCR detection of staphylococcal enterotoxin genes in *Staphylococcus* spp. strains isolated from meat and dairy products. Evidence for new variants of *S. aureus* in *S. aureus* AB-8802. J Appl Microbiol 97: 719–730.

24. Sanderson A, Strominger J, Nathenson S (2000) Multiple sequence typing for characterization of meticillin-resistant and meticillin-susceptible clones of *Staphylococcus aureus*. J Clin Microbiol 38: 1008–15.

25. McCullum N, Karauzum H, Getzmann R, Bischoff M, Majcherczyk P, et al. (2008) Linking genomic change to community evolution: insights from studies of bacteria and bacteriophage. Environm Microbiol 9: 3134–3142.

26. Sanderson A, Strominger J, Nathenson S (1998) Bacteriophage resistance mechanisms. Nat Rev Microbiology 8: 317–327.

27. Sanderson A, Strominger J, Nathenson S (1996) Chemical structure of teichoic acid from *Staphylococcus aureus*, strain Copenhagen. J Biol Chem 271: 3603–3613.

28. McCallum N, Kauranen N, Hetzmann R, Bischoff M, Majcherczyk P, et al. (2006) In vivo survival of teicoplanin-resistant *Staphylococcus aureus* and fitness cost of teicoplanin resistance. Antimicrob Agents Chemother 50: 2352–2360.

29. Baggesen D, Wegener H, Madsen M (1997) Correlation of conversion of *Salmonella enterica serovar enteritides* phage type 1, 4 or 6 to phage 7 with loss of lipopolysaccharide. J Clin Microbiol 35: 330–333.

30. Goorke C, Gressinger M, Endler K, Breitkopf C, Wardlech C, et al. (2007) High phenotypic diversity in infecting but not in colonizing *Staphylococcus aureus* populations. Environm Microbiol 9: 3134–3142.

31. Wardenburg JB, Snehed G (2008) Vaccine protection against *Staphylococcus aureus* pneumonia. J Exp Med 205: 287–294.

32. Goodner K, Herfall P (1935) The protective action of Type 1 antipneumococcus serum in mice. I. Quantitative aspects of the protective test. J Exp Med 62: 359–374.

33. Taborda C, Rivera J, Zaragoza O, Casadevall A (2003) More is not necessarily better: prozone-like effects in passive immunization IgG. J Immunol 170: 3621–3630.

34. Sparano JA, Wolf A, Brown D (2000) Tropoins for predicting cardiotoxicity from cancer therapy. Lancet 356: 1947–1948.

35. Yeh ET (2006) Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57: 485–491.

36. Dinarello CA (1996) Cytokines as mediators in pathogenesis of septic shock. In Pathology of septic shock. Current Topics in Microbiology and Immunology. Vol 216. EiRienchi, HWagner, eds. Berlin: Springer-Verlag. pp 135–165.

37. Hu DL, Ono H, Sasaki S, Shiznuami H, Sakuraba H, et al. (2005) Vaccination with non-toxin mutant toxic shock syndrome toxin I protects against *Staphylococcus aureus* infection. J Infect Dis 188: 743–752.

38. Nilsson IM, Patti JM, Bernell T, Hook TM, Tarkowski A (1998) Vaccination with a recombinant fragment of collagen adhesion provides protection against *Staphylococcus aureus*-mediated septic death. J Clin Invest 101: 2649–2649.

39. Kuklin N, Clark D, Secore S, Cook J, Cope L (2006) A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody response in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74: 2211–2223.

40. Telford JL (2006) Bacterial genome variability and its impact on vaccine design. Cell Host & Microbe 3: 486–416.

41. Winzeier EA (2008) Malaria research in the post-genomic era. Nature 455: 731–736.

42. Bohannan BJ, Lenski RE (2000) Linking genetic change to community evolution: insights from studies of bacteria and bacteriophage. Ecol Lett 3: 362–377.

43. Labrie S, Samson J, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiology 8: 317–327.

44. Hornscheeck CK, Joisy E, Deska L, Izhar M, Stocker MB (1991) Immunity conferred by Aro-Salmonella live vaccines. Microb Pathog 9: 149–158.

45. McKenney D, Kimberley L, Poulter B, Wang Y, Murthy V, et al. (1999) Broadly protective vaccine for *Staphylococcus aureus* based on an in vivo-expressed antigen. Science 281: 1523–1527.

46. O’Riordan K, Lee J (2004) *Staphylococcus aureus* capsular polysaccharides. Clin Microbiol Rev 17: 218–234.

47. Middelboe M, Hristov K, Blackburn N, Sinn R, Fischer U, et al. (2001) Effect of bacteriophage on the population dynamics of four strains of pelagic marine bacteria. Microb Ecol 42: 395–406.

48. Ledberg J (1996) Smaller fleas…ad infinitum: therapeutic bacteriophage redux. Proc Natl Acad Sci USA 93: 3167–3168.